ORGO
Organogenesis Holdings Inc.
Drug Manufacturers - Specialty & Generic · Healthcare · United States
0.77
close · 2026-10-30
value
85
cheaper than peers85
quality
13
stronger fundamentals13
ranked against
Drug Manufacturers - Specialty & Generic
value
quality
41 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, latest year | 19.5% | 99 |
| price to sales | 0.22× | 99 |
| price to book | 0.67× | 96 |
| earnings yield, 3 years ago | 15.6% | 91 |
| earnings yield, 2 years ago | 5.2% | 86 |
| cash flow yield, 2 years ago | 6.6% | 77 |
| cash flow yield, 1 year ago | 4.2% | 65 |
| earnings yield, 1 year ago | -1.3% | 57 |
| cash flow yield, 3 years ago | -9.1% | 26 |
| cash flow yield, latest year | -24.7% | 4 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 23.2% | 79 |
| return on equity | -25.9% | 31 |
| operating margin | -119.3% | 6 |
| revenue growth | -56.7% | 4 |
4 of 4 measures available
Facts
| market cap | $99M |
| free cash flow | $28.4M |
| employees | 854 |
| first trade | 2017-01-05 |
| next earnings | 2026-11-05 |
| fundamentals updated | 2026-08-21 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 0.15 | -0.01 | 0.04 | 0.12 |
| free cash flow | -$24.5M | $4.2M | $6.6M | -$9.0M |
| net income | $37.0M | $861,000 | $4.9M | $15.5M |
| revenue | $563.0M | $482.0M | $433.1M | $450.9M |
| unusual items | -$11.2M | -$22.8M | $0 | $0 |